What is it about?
Children in developing countries have lower cancer survival rates due to poor access to medicines. This study aimed to create a guidance framework to improve access to childhood cancer medicines in developing countries through a global access platform launched by WHO and St. Jude Children's Hospital. Key recommendations include partner-driven approaches, integrating with existing programs, strengthening primary care, and involving communities to ensure effective implementation.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
This study is important because it addresses the urgent issue of low childhood cancer survival rates in developing countries, where access to essential medicines is severely limited. Its uniqueness lies in using a stakeholder-informed approach to create a practical framework tailored to the specific challenges in these regions. By offering actionable solutions, such as integrating efforts with existing health programs and engaging local communities, this research could improve the effectiveness of global initiatives like the WHO-St. Jude platform. The timely implementation of this framework could also increase survival rates and save numerous children by ensuring they have access to life-saving cancer medicines.
Perspectives
This research is crucial in addressing the significant disparity in childhood cancer survival rates between developing and high-income countries. Its strength lies in its stakeholder-informed approach, which ensures the framework is practical, context-specific, and grounded in the realities faced by health systems in developing regions. Focusing on collaboration and integration with existing health programs offers a realistic path to improving access to essential childhood cancer medicines.
Otuto Amarauche Chukwu
University of Toronto
Read the Original
This page is a summary of: Improving childhood cancer medicines access in developing countries: Towards an implementation framework to inform the Global Platform for Access to Childhood Cancer Medicines for Nigeria, PLOS Global Public Health, September 2024, PLOS,
DOI: 10.1371/journal.pgph.0003275.
You can read the full text:
Contributors
The following have contributed to this page
